Skip to content
MARKETS / NASDAQ / VCYT
NASDAQ · SERVICES-MEDICAL LABORATORIES · LARGE CAP

Veracyte, Inc. VCYT

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$517.1M
▲ 16.0% YoY
$66.4M
▲ 174.9% YoY
$126.6M
▲ 98.5% YoY
In brief

What this company does

Veracyte, Inc. offers tests in the United States for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). In the United States, it offers laboratory developed tests through CLIA-certified laboratories in South San Francisco and San Diego, California, supported by cytopathology operations in Austin, Texas, and outside the United States it provides in vitro diagnostic tests through distribution to laboratories and hospitals that perform the tests locally. The majority of its revenue currently comes from sales of its Decipher Prostate and Afirma tests. As of December 31, 2025, it had 755 employees. The company was incorporated in Delaware as Calderome, Inc. in August 2006, operated as an incubator until early 2008, and changed its name to Veracyte, Inc. in March 2008.

Written from the business description in VERACYTE, INC.'s annual report to the U.S. Securities and Exchange Commission, filed 26 February 2026. Every sentence was checked against that document before publication.

Growth
USD 517.1M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 517.1 · Net income 66.4
200M400M-40M20112013201520172019202120232025
Compound annual growth
+20.4%
+34.5%
+26.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +34.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
13 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 11.2% · Net 12.8%
-200%-400%20112013201520172019202120232025
ROE
FY2025 · ROE 5.3%
-20%-40%-60%20112013201520172019202120232025

Each USD of equity produced 5 cents of profit this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 126.6
50M100M-20M20112013201520172019202120232025

Total assetsUSD 1.4B
EquityUSD 1.3B
CashUSD 362.6M
Current ratio8.15×

Equity funds 93% of total assets.

The 15-year record
15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B0.50.40.40.30.20.10.10.10.10.10.00.00.00.00.0
Operating income $B0.10.0−0.1−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B0.10.0−0.1−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.0−0.00.0−0.00.00.00.00.00.00.00.00.0··
Net income $B0.10.0−0.1−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B0.10.10.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $0.820.31−1.02−0.51−1.11−0.66−0.27−0.62−0.91−1.09−1.30−1.36−6.15−28.68−24.90
Dividend / sh $···············
Payout %···············
ROE %5.32.2−7.0−3.4−10.0−10.6−7.9−39.3−64.1−56.6−72.8−60.1···
Shares out B0.080.080.070.070.070.060.050.040.030.030.030.020.020.00·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 58 reconciliationsAUDITED

Reconciled in 15 of 19 fiscal years. 28 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Medical Laboratories
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2011

Share this section

Download image